Date: 2014-12-03
Type of information: Nomination
Compound: chief financial officer
Company: Paratek Pharmaceuticals (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 3, 2014, Paratek Pharmaceuticals announced Douglas Pagán will join Paratek's executive leadership team as chief financial officer, effective December 18. Mr. Pagán will report to Michael F. Bigham, Chairman and Chief Executive Officer of Paratek. Paratek's primary focus, as a late stage antibiotics company, is on the development and commercialization of omadacycline – a broad-spectrum intravenous and oral once daily antibiotic candidate for serious community-acquired infections where resistance is of concern. Douglas Pagan most recently served as Vice President Finance at Acceleron Pharma Inc., which he joined in 2008. Prior to Acceleron, Mr. Pagán served in financial management roles at Biogen Idec and BMS. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson and Johnson. Mr. Pagán earned his BSE in Chemical Engineering from Princeton University. He earned his MBA from Columbia Business School with concentrations in Finance and Accounting. Mr. Pagán will succeed Kathryn Boxmeyer, Paratek's current interim CFO, who is stepping down to pursue other opportunities.
Financial terms:
Latest news:
Is general: Yes
